Exicure company info

What does Exicure do?
Exicure (NASDAQ:XCUR) is a pioneering biotechnology firm deeply engaged in the design and development of therapeutics based on its proprietary spherical nucleic acid (SNA™) technology. These advanced therapeutics have a wide range of applications, including gene regulation and immunotherapy. Exicure's main goal is to harness the power of SNA to unlock new possibilities in the treatment of diseases with genetic origins or for which traditional approaches have been inadequate. The company focuses on advancing its pipeline of innovative treatments through rigorous clinical trials, with the aim of addressing unmet medical needs and improving patient care. By pushing the boundaries of science and technology, Exicure strives to make a significant impact on medicine and healthcare.
Exicure company media
Company Snapshot

Is Exicure a public or private company?

key
Ownership
Public

How many people does Exicure employ?

people
Employees
7

What sector is Exicure in?

pie chart
Sector
Health Care

Where is the head office for Exicure?

location pin
Head Office
Chicago, United States

What year was Exicure founded?

founded flag
Year Founded
2011
What does Exicure specialise in?
/Gene Therapy /Tumor Immunotherapy /Drug Discovery /RNA Technology /Clinical Trials /Nanotechnology Medicines

What are the products and/or services of Exicure?

Overview of Exicure offerings
Spherical Nucleic Acids (SNA) technology for precision medicine, targeting genetic diseases.
Development of cavrotolimod (AST-008) as an immuno-oncology therapeutic for solid tumors and lymphomas.
Collaboration on hair loss treatment focusing on androgenetic alopecia.
Research into neurological disorder treatments, including Huntington's and Parkinson's diseases.
Partnerships for dermatological applications of SNA technology, addressing psoriasis and atopic dermatitis.
Exploration of COVID-19 therapies utilizing proprietary SNA technology.

Who is in the executive team of Exicure?

Exicure leadership team
  • Mr. Paul  Kang
    Mr. Paul Kang
    CEO & Director
  • Ms. Jiyoung  Hwang
    Ms. Jiyoung Hwang
    CFO & Director
  • Mr. Joshua  Miller
    Mr. Joshua Miller
    Chief Accounting Officer
  • Mr. Bart  Anderson
    Mr. Bart Anderson
    Senior Director of R&D